MAB Discovery expands 2013 partnership with BioNTech AG

German MAB Discovery GmbH has extended its 2013 collaboration with BioNTech AG by a contract to produce another set of therapeutic antibodies against a range of targets delivered by BioNTec.

MAB Discovery will use its rabbit-based antibody discovery platform to generate novel antibody therapeutics against undisclosed targets provided by BioNTech. Financial terms of the agreement were not disclosed. BioNtech recently partnered with Genentech to develop personalised RNA-based cancer vaccines.

MAB Discovery delivers high quality, functional monoclonal antibodies via sophisticated, high-throughput selection of B cells generated by immunisation, and delivers a vast number of high quality candidates with regard to potency and epitope coverage. The use of wild type rabbits for immunisation and the functional B-cell cloning strategy of MAB Discovery suits not only classical target proteins and receptors, but also to a wide variety of more challenging immunogens, e.g. GPCRs, ion channels, carbohydrates, and small sized epitopes.

The immune system of rabbits differs from that of mice or humans in that it produces a diverse number of high-affinity antibodies in response to almost any antigen. An additional advantage is the animals’ size –unlike mice, rabbits are big enough for multiple blood samples to be taken over time, allowing the exploration of mAbs at different stages of maturation and capturing the full diversity of the immune response to cover all possible epitopes.

Italian TES Pharma s.r.l. (Perugia) has presented preclinical results of TES-991 and a backup compound, both enhancers of mitochondrial...

Sign up for our newsletter

Your e-mail-address is already registered.

Your e-mail address will be used solely for the purposes of sending out our newsletter. You will be able to unsubscribe at any time and thereby revoke your consent to receive the newsletter. A transfer of the data to third parties will not occur. For further information, please refer to our privacy policy.

Free Newsletter

Free Newsletter!Always up to date!All news at one glance!All important events!Your e-mail-address is already registered.

Your e-mail address will be used solely for the purposes of sending out our newsletter. You will be able to unsubscribe at any time and thereby revoke your consent to receive the newsletter. A transfer of the data to third parties will not occur. For further information, please refer to our privacy policy.